BillionToOne (BLLN)

Executive Summary

BillionToOne is a publicly traded precision diagnostics company that leverages its proprietary single-molecule next-generation sequencing (smNGS) platform to detect disease-causing DNA with ultra-high sensitivity. The company commercializes two core product suites: UNITY for non-invasive prenatal testing (NIPT) and Northstar for pan-cancer liquid biopsy. Northstar enables early cancer detection from cell-free DNA, addressing a large addressable market. With an estimated valuation of $3.8B, the company has strong commercial traction and is advancing clinical trials evaluating its liquid biopsy in gastroesophageal and pancreatic cancers. Its technology offers potential advantages in sensitivity and specificity, positioning it well in the competitive diagnostics landscape.

Upcoming Catalysts (preview)

• Q4 2026Interim data readout from Northstar liquid biopsy in gastroesophageal adenocarcinoma trial (NCT05733689, Phase 1)60% success
• Q3 2026Interim data readout from Northstar liquid biopsy in metastatic pancreatic ductal adenocarcinoma trial (NCT07096362, Phase 2)55% success
• Q3 2026Expansion of UNITY NIPT market share into new geographies or partnership announcements70% success